Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Postmenopausal Bone Loss with Intermittent Alendronate
2006-005862-38Phase 3Completed
- Sponsor
- CHU UCL Namur - Site Mont-Godinne
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteopenia and osteoporosis comparing Alendronate 70 mg once every two weeks with Placebo once every two weeks (2 arms). Primary endpoint: Lumbar spine BMD change at 2 years. Started Mar 2007; status: completed.
02
Drugs
alendronate
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on 2006-005862-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005862-38.